Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • APLS (NMS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

617 977 5700 100 Fifth Avenue, Waltham, MA 02451, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why Apellis Pharmaceuticals Stock Is Suddenly Surging - TipRanks
TipRanks • Jan 7
Apellis stock jumps nearly 8% as investors look to JPM healthcare update - TechStock²
TechStock² • Jan 7
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Seeking Alpha • Dec 12
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Navigating a 40.73% Potential Upside in the Biotech Space - DirectorsTalk Interviews
DirectorsTalk Interviews • Jan 6
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
MSN • Jan 2

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Apellis Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Apellis Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Apellis Pharmaceuticals, Inc. have?
Apellis Pharmaceuticals, Inc. has approximately 705 employees.
What industry is Apellis Pharmaceuticals, Inc. in?
Apellis Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Apellis Pharmaceuticals, Inc. a publicly traded company?
Yes, Apellis Pharmaceuticals, Inc. is publicly traded under the ticker symbol APLS on the NMS. The company has a market capitalization of approximately $3.16 billion.
Where is Apellis Pharmaceuticals, Inc. headquartered?
Apellis Pharmaceuticals, Inc. is headquartered in Waltham, MA, United States at 100 Fifth Avenue, Waltham, MA 02451, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.